Plain-English translation of NCT07246668 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining carbon ion radiotherapy — a precise form of radiation — with two immunotherapy medications called atezolizumab and bevacizumab can help treat advanced hepatocellular carcinoma (a type of liver cancer). The trial will enroll about 52 patients with advanced liver cancer who cannot have surgery. Researchers want to see if adding this special radiation therapy to the immunotherapy medications helps control tumors better while keeping side effects manageable.
Advanced liver cancer is often difficult to treat, and while these two immunotherapy medications have shown promise, adding targeted radiation directly to the tumor may help improve outcomes by combining local tumor control with the body's immune response.
You likely qualify if…
You likely don't qualify if…
You will receive two immunotherapy medications by IV infusion every 3 weeks. During the early phase of treatment, you will also undergo carbon ion radiotherapy, a specialized radiation delivered in 4–12 sessions tailored to your tumor. After radiation is complete, you will continue the immunotherapy medications as maintenance therapy until your cancer stops responding, side effects become too severe, or you choose to stop. Throughout the study, your doctors will monitor your health with regular blood tests, scans, and check-ins over approximately 3 years.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea